Moleculin Biotech shares fall 5.11% intraday despite promising preclinical data for Annamycin.

Moleculin Biotech, Inc. declined 5.11% in intraday trading, despite the company unveiling promising preclinical data for its lead drug candidate, Annamycin. The data highlights the potential of Annamycin for treating a broad range of human cancers, including high-need oncology indications. Annamycin is currently in late-stage clinical development in combination with cytarabine for the treatment of AML, with an anticipated preliminary data readout in the second half of 2025.